Lipid-Modifying Therapies and Stroke Prevention

被引：0
|
作者：
Daniel G. Hackam
Robert A. Hegele
机构：
[1] Western University,Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry
[2] Western University,Department of Epidemiology and Biostatistics
[3] Western University,Department of Clinical Neurological Sciences
[4] Western University,Division of Endocrinology and Metabolism, Department of Medicine, Schulich School of Medicine and Dentistry
来源：
Current Neurology and Neuroscience Reports | 2022年 / 22卷
关键词：
Ischemic stroke; Hemorrhagic stroke; Low-density lipoprotein; Triglyceride; Statin; Proprotein convertase subtilisin/kexin type 9;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：375 / 382
页数：7
相关论文
共 50 条
  • [31] Observational study of patients from a Lipid Unit on lipid-modifying therapy for primary and secondary prevention: ULFI Study
    Vila, Alex
    Pons, Estel
    Garcia, Patricia Trinidad
    Vidal, Daniel
    Lopez, Sara
    Grau, Armand
    [J]. CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2023, 35 (06): : 272 - 279
  • [32] Association of Non-LDL Indices with Recurrent Stroke Risk while on Lipid-Modifying Therapy
    Park, Jong-Ho
    Ovbiagele, Bruce
    [J]. JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2020, 27 (02) : 144 - 154
  • [33] Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development
    Duong, MyNgan
    Nicholls, Stephen J.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (07) : 753 - 761
  • [34] Lipid-Modifying Treatments for Heart Failure: Is Their Use Justified?
    Cleland, John G. F.
    Hutchinson, Kate
    Pellicori, Pierpaolo
    Clark, Andrew
    [J]. HEART FAILURE CLINICS, 2014, 10 (04) : 621 - +
  • [35] Clinical trials of lipid-modifying agents: design considerations
    Bowman, Louise
    Haynes, Richard
    Armitage, Jane
    [J]. CLINICAL LIPIDOLOGY, 2011, 6 (01) : 109 - 116
  • [36] Effects of different lipid-modifying drugs an lipoprotein subclasses
    Segrest, JP
    Osterlund, LC
    Henkin, Y
    [J]. CIRCULATION, 1999, 100 (18) : 257 - 258
  • [37] Trends in lipid-modifying agent use in 83 countries
    Blais, Joseph E.
    Wei, Yue
    Yap, Kevin K. W.
    Alwafi, Hassan
    Ma, Tian-Tian
    Brauer, Ruth
    Lau, Wallis C. Y.
    Man, Kenneth K. C.
    Siu, Chung Wah
    Tan, Kathryn C. B.
    Wong, Ian C. K.
    Wei, Li
    Chan, Esther W.
    [J]. ATHEROSCLEROSIS, 2021, 328 : 44 - 51
  • [38] Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases
    Ge, Mengyuan
    Merscher, Sandra
    Fornoni, Alessia
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (08):
  • [39] CONTRIBUTION OF MULTIPLE COMPONENTS TO THE LIPID-MODIFYING EFFECTS OF XUEZHIKANG
    Duan, Z.
    Guo, S.
    Capuzzi, D.
    Li, S.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [40] Severe hypertriglyceridaemia in patients treated with lipid-modifying agents
    Desamericq, G.
    Van Ganse, E.
    Schwalm, M. -S.
    Bourke, A.
    Moulin, P.
    [J]. DIABETES & METABOLISM, 2012, 38 (03) : 277 - 279
12345